Wolfe Research Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $7
Benzinga Newsdesk 6 months ago
NewsPrice TargetInitiationAnalyst Ratings
Wolfe Research analyst Andy Chen initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $7.
Wolfe Research analyst Andy Chen initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $7.